Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
ELEV Price/Volume Stats
Current price | $0.58 | 52-week high | $5.83 |
Prev. close | $0.58 | 52-week low | $0.44 |
Day low | $0.56 | Volume | 305,600 |
Day high | $0.59 | Avg. volume | 1,541,936 |
50-day MA | $0.58 | Dividend yield | N/A |
200-day MA | $2.47 | Market Cap | 34.35M |
ELEV Stock Price Chart Interactive Chart >
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
ELEV Price Returns
1-mo | -11.27% |
3-mo | -28.29% |
6-mo | -84.90% |
1-year | 25.62% |
3-year | -90.94% |
5-year | N/A |
YTD | 8.01% |
2023 | -43.47% |
2022 | -84.22% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...